Invest now

Concord Biotech share price

Balanced risk
  • 45%Low risk
  • 45%Moderate risk
  • 45%Balanced risk
  • 45%High risk
  • 45%Extreme risk
  • ₹580.15(-2.41%)
    November 16, 2026 15:26:17 PM IST
    • NSE
    • BSE
  • Vol : 357.54 K (NSE + BSE)
    Last 20 day avg : 345.00 K
Concord Biotech is trading -2.41% lower at Rs 580.15 as compared to its last closing price. Concord Biotech has been trading in the price range of 592.90 & 577.40. Concord Biotech has given -11.71% in this year & -6.10% in the last 5 days. Concord Biotech has TTM P/E ratio 50.97 as compared to the sector P/E of 38.85.There are 4 analysts who have initiated coverage on Concord Biotech. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 70.65 Crores in its last quarter.Listed peers of Concord Biotech include Sun Pharmaceutical Industries (-0.74%), Divi's Laboratories (-3.30%), Torrent Pharmaceuticals (0.60%).The Mutual Fund holding in Concord Biotech was at 5.85% in 5 Nov 2026. The MF holding has increased from the last quarter. The FII holding in Concord Biotech was at 7.33% in 5 Nov 2026. The FII holding has increased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Key Metrics

Updated on 16 Nov 2026, 04:29 PM IST

  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.00
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.63
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    6.24
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    44.66
    Lower than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    15.89
    Indicates overvaluation
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -
Price range
Day Range
Lowest
577.40
Highest
592.90
52 week range
Lowest
493.53
Highest
807.03
Concord Biotech Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
1,866.95-0.744,47,933.2938.405.550.830.47
Divi's Laboratories
11,111.00-3.302,94,962.1373.3211.480.410.03
Torrent Pharmaceuticals
4,689.950.601,78,384.2472.7319.220.80141.16
Cipla
1,394.000.071,12,615.4627.573.330.921.11
Zydus Lifesciences
1,189.00-0.171,18,603.2121.194.240.0914.22
Mutual Fund Ownership
View all
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 85.64
  • % of AUM 2.89
LIC MF Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 2.16
  • % of AUM 2.56
Baroda BNP Paribas Innovation Fund Regular Growth
NA
  • Amount Invested (Cr.) 21.42
  • % of AUM 2.15
Baroda BNP Paribas Large and Mid Cap Fund Regular Growth
3/5
  • Amount Invested (Cr.) 31.48
  • % of AUM 1.99
SBI Healthcare Opportunities Fund Regular Growth
NA
  • Amount Invested (Cr.) 69.94
  • % of AUM 1.90
Concord Biotech Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-10-27Quarterly Results
2026-09-23Bonus issue
2026-07-31Quarterly Results
2026-05-29Audited Results & Final Dividend
2026-02-11Quarterly Results
About the company Concord Biotech
  • IndustryBiotechnology & Drugs
  • ISININE338H01029
  • BSE Code543960
  • NSE CodeCONCORDBIO
Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.
  • Management Info
  • Sudhir VaidExecutive Chairman of the Board, Managing Director
  • Ankur VaidChief Executive Officer, Joint Managing Director, Executive Director
  • Raviraj KariaChief Financial Officer
  • Paritosh TrivediCompliance Officer, Company Secretary
  • Devang BhattVice President - Sales and Marketing, Head - Limbasi Plant - 3
  • Manoj KumarVice-President - Formulation Division and Head - Valthera Unit - 2
  • Sundeep BenganiGeneral Manager - International Business Development, Formulation Division
Concord Biotech Share Price FAQs

Concord Biotech is trading at 580.15 as on Mon Nov 16 2026 09:56:17. This is -2.41% lower as compared to its previous closing price of 594.50.

The market capitalization of Concord Biotech is 6102.90 Cr as on Mon Nov 16 2026 09:56:17.

The average broker rating on Concord Biotech is Buy. The breakup of analyst rating is given below -

  • 1 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 2 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Concord Biotech is 807.03 whereas the 52 wk low is 493.53

Concord Biotech can be analyzed on the following key metrics -

  • TTM P/E: 50.97
  • Sector P/E: 38.85
  • Dividend Yield: 0.64%
  • D/E ratio: 0.00

Concord Biotech reported a net profit of 260.91 Cr in 2026.

The Mutual Fund Shareholding was 5.85% at the end of 5 Nov 2026.